💸 The Tape

Innovative Industrial Properties reported a third quarter that will read very differently depending on which line you look at. AFFO per share rose 15% to $1.96, net income to common came in at $0.99 a share, and the $1.90 quarterly dividend, a 7.6% yield at recent prices, is comfortably covered. Executive Chairman Alan Gold called it “strong earnings,” and on the per-share math he’s right.

Then look at where the earnings came from. Total revenue was flat at $64.9 million. The growth came from interest and other income, which more than tripled to $14.3 million, with $10.4 million of that from IQHQ, the life-science real estate platform IIP has been funding since last year. Strip out the non-cannabis income and the core rental business is treading water while the tenant roster keeps churning.

The tenant ledger

IIP has spent two years working through the collapse of its mid-tier cannabis tenant base, and the third quarter closed several of those chapters. PharmaCann’s leases are all terminated as of September 30, with the New York facility re-leased to Grown Rogue in August. Parallel defaulted on two Florida leases in July and IIP took them back in August. The Cannabist handed back seven properties in September; twelve remain leased at just 1.5% of annualized rent. Battle Green’s lease was assigned to a Vireo affiliate with a parent guaranty, which is as good as a cannabis credit gets right now.

The big one still open is 4Front, at 7.1% of contractual rent across three properties. IIP has tentative arrangements for the 250,000-square-foot Illinois asset and two Massachusetts facilities, contingent on receivership, with effect expected around year-end or early 2027. If those close, the last major default workout is behind it.

The gross activity numbers are striking: 16 leases terminated covering 1.2 million square feet, and six new leases signed for 604,000 square feet in a single quarter. A post-quarter lease on a 270,000-square-foot Saxton, Pennsylvania property is pending license transfer approval. The pattern is consistent. Space comes back from distressed operators, gets re-leased at lower rent to healthier ones, often with a parent guarantee, and IIP applies security deposits to cushion the gap. $11.6 million in Q3 came from defaulted tenants’ payments and deposits combined, up from $10.5 million in Q2. That’s income, but it’s non-recurring income from a shrinking pool.

The pivot is now the strategy

The headline number IIP chose to lead with was $275 million of investment activity, and none of it is cannabis. A $245 million mezzanine loan commitment for Alewife Park, a life-science campus, funded $111 million at closing at a 15.8% expected yield with a 14% floor. Another $30 million of IQHQ Series G preferred went in during September, bringing total IQHQ exposure to $300 million across a revolver and preferred equity.

Those are good yields. They’re also a different business. IIP’s original pitch was sale-leaseback financing to cannabis operators who couldn’t access bank debt, at 12 to 15% cap rates backed by hard assets in limited-license states. That trade worked spectacularly until the operators couldn’t pay. Now the company is deploying capital into life-science mezzanine debt and preferred equity, where the yields are similar but the borrower can get a bank loan if it wants one. IIP is a cannabis landlord that has become a specialty credit fund with a cannabis real estate portfolio attached, and the quarter’s earnings growth came entirely from the credit side.

The balance sheet

This is still the strongest capital structure in cannabis-adjacent real estate. Net debt to gross assets is 18.7%, net debt to adjusted EBITDA is 2.1x, and cash stands at $142.4 million against $711.6 million of total debt. In October IIP collected $49 million in seller financing from the Perth, New York sale and raised $54.2 million through a 9.25% Series B preferred offering. The $87.5 million revolver was extended 90 days to January 21, 2027, which is a short runway and suggests a longer-term refinancing is being negotiated.

A 9.25% preferred is expensive money for a REIT with 2x leverage. It tells you the common equity is too cheap to issue and the debt markets want a premium for cannabis exposure even when the use of proceeds is life-science lending. Shares outstanding fell slightly to 27.6 million without a disclosed buyback program, likely through forfeitures and tax withholding.

What’s missing

The release offers no portfolio-level occupancy, no rent collection rate, no property count, and no guidance. Those omissions matter for a REIT whose investment case rests on stability. The dividend is covered by AFFO at roughly 97%, which is tight for a company whose highest-margin income is now security deposits and mezzanine interest. Full rescheduling to Schedule III would help IIP’s tenants on 280E and improve their ability to pay, but it also opens the door to bank financing, which erodes the very scarcity that made IIP’s sale-leaseback model profitable. The company’s pivot into life science looks like a hedge against both outcomes.

The read

IIP is executing a managed transition. It’s cleaning up a tenant base that was never as creditworthy as the original cap rates implied, re-leasing to the operators that survived, and redeploying capital into a sector where 15% yields don’t require a DEA ruling. AFFO growth is real but it’s borrowed from IQHQ, not earned from cannabis rent. The dividend holds for now. Whether it holds in 2027 depends on 4Front closing, the Saxton lease transferring, and the revolver getting a real extension rather than another 90 days. For a company that spent five years as the sector’s one safe yield, that’s a lot of contingencies in a single quarter.

📈 Dog Walkers

$TLRY ( ▲ 0.79% ) Cuts Capacity and Raises the Floor

Tilray’s Canadian cannabis plan announced Monday is a facility consolidation dressed up as a strategy, and on those terms it’s sensible. The company is closing Foss, the Fenwick, Ontario greenhouse it inherited with Redecan, shifting cultivation to Masson, Quebec and pre-roll production to Cayuga, Ontario, with Foss winding down by January 31, 2027. Target: US$10 million in annualized savings by fiscal 2028. Adjusted EBITDA guidance for fiscal 2027 moved from $68 to 75 million to $70 to 75 million, which is a floor raise, not a ceiling raise, and tells you the savings are already baked in.

The logic is clean. Tilray has 4.2 million square feet of Canadian cultivation across Leamington, Cayuga, Masson and Broken Coast, far more than a market with flat retail sales and compressing prices needs. Shutting a greenhouse and pushing Masson from 32.5 to 50 metric tonnes through yield gains is the cheapest capacity Tilray will ever add. Pre-rolls are a third of its Canadian adult-use sales and grew 28% last year, so centralizing that in Cayuga is the right production to protect. And re-establishing Masson’s EU-GMP certification in 2027 is the move that matters for margin, because international medical flower sells for multiples of Canadian rec.

Here’s where the skepticism belongs. Ten million in savings is roughly 1% of Tilray’s revenue and the lower end of guidance moved by two million. That’s rounding error for a company that just posted a $40 million net loss. Redecan was a $925 million acquisition built on a reputation for quality that came from Foss specifically; Tilray says supply won’t be interrupted, but moving a brand’s genetics and grow environment 600 kilometers is not a no-risk exercise. No headcount figure, no revenue disclosure, and the “future U.S. markets as regulations allow” line is the same promise Tilray has been making since 2019.

So: not a crock. A competent, overdue rationalization of an oversized footprint, with a credible EU-GMP catalyst attached. Just don’t mistake a greenhouse closure for a turnaround. Canadian cannabis is a cost-cutting business now, and Tilray is cutting.

📺 Trade To Black

Who Qualifies for DEA Registration, and Who Doesn't | TTB Presented by Flowhub

• Jushi Chairman and CEO Jim Cacioppo joins to break down Q3 results: revenue up 7% to $70.5M, adjusted EBITDA of $13.6M at a 19.3% margin, and a net loss narrowed to $12.5M.

• Wholesale jumped 40% to a record $9.7M for the second straight quarter, and Virginia posted another record for retail and delivery sales with adult-use set to launch July 1, 2027. Cacioppo covers key markets and what investors should watch as earnings season rolls on.

• Dentons’ Eric Berlin returns to unpack the DOJ’s announcement that the DEA is registering 900+ medical dispensaries in seven states, with nearly 7,000 businesses applying, and why dual-licensed medical and recreational operators are being rejected under the April order.

• Berlin also explains how the registrations interact with the separate Schedule III proceeding before Judge Derek Julius, what it means for operators and investors, and what could come next.